


<b>Name</b>	Jin Woo Song, MD, Ph.D	
<b>Country</b>	Republic of Korea	
<b>Organization</b>	University of Ulsan College of Medicine, Asan Medical Center	
<b>Current Position</b>	Professor	

### Educational Background

2009.3-2011.2 Ph.D. in Internal Medicine, Graduate School, University of Ulsan. Seoul, Republic of Korea  
2002.3-2004.2 M.S. in Internal Medicine, Graduate School, University of Ulsan. Seoul, Republic of Korea  
1993.3-1999.2 M.D., College of Medicine, Chung-Ang Univ., Seoul, Republic of Korea

### Professional Experiences

2020- Professor, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea  
2014-2020 Associate Professor, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea  
2009-2014 Assistant Professor, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea  
2012-2013 Research Fellow, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A  
2007-2009 Clinical Fellow, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, Republic of Korea

### Professional Organizations

Academic societies:

The Korean Academy of Tuberculosis and Respiratory Disease: ILD study group, Deputy head  
The Asian Pacific Society of Respiriology: ILD assembly, Deputy head  
The American Thoracic Society: ILA Consensus Statement Committee

Associate editor/Editorial board member: *Tuberculosis and Respiratory Disease*, *Korean Journal of Internal Medicine*, *CHEST(past)*, *BMC pulmonary medicine*, *Pulmonary Therapy*, *Frontiers in Medicine*

### Main Scientific Publications

1. Yoon HY, Park JS, Lee SE, Moon SJ, Song JW. Circulating mitochondrial DNA as a biomarker of survival in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J*. 2023 Jan 19;61(1):2201984.
2. Kim SH, Adams TS, Hu Q, Shin HJ, Chae G, Lee SE, Sharma L, Kwon HK, Lee FY, Park HJ, Huh WJ, Manning E, Kaminski N, Sauler M, Chen L, Song JW, Kim TK, Kang MJ. VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis. *Am J Respir Cell Mol Biol*. 2023 Jul;69(1):22-33
3. Inoue Y, Wells AU, Song JW, Xu Z, Kitamura H, Suda T, Okamoto M, Müller H, Coeck C, Rohr KB, Kolb M, Brown KK. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. *Respirology*. 2023 May;28(5):465-474.
4. Yoon HY, Kim SY, Kim OJ, Song JW. Nitrogen dioxide increases the risk of disease progression in idiopathic pulmonary fibrosis. *Respirology*. 2023 Mar;28(3):254-261.

- 
5. Kwon BS, Lee HY, Choe J, Chae EJ, Hong S, Song JW. Acute Respiratory Deterioration in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Single-Center Study. *Chest*. 2022 Jul;162(1):136-144.
  6. Kim HS, Moon SJ, Lee SE, Hwang GW, Yoo HJ, Song JW. The arachidonic acid metabolite 11,12-epoxyeicosatrienoic acid alleviates pulmonary fibrosis. *Exp Mol Med*. 2021 May;53(5):864-874.
  7. Yoon HY, Kim SY, Kim OJ, Song JW. Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis. *Eur Respir J*. 2021 May;57(5)
  8. Song JW, Ogura T, Inoue Y, Xu Z, Quaresma M, Stowasser S, Stansen W, Crestani B. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON. *Respirology*. 2020 Apr;25(4):410-416.
  8. Behr J, Kolb M, Song JW, Luppi F, Schinzel B, Stowasser S, Quaresma M, Martinez FJ. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). *Am J Respir Crit Care Med*. 2019 Dec 15;200(12):1505-1512.
  9. Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. *Lancet Respir Med*. 2019 Jan;7(1):60-68.
  10. Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, Adams F, Kokosi M, Devaraj A, Renzoni E, Maher TM, Kim DS, Wells AU. Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease. *EBioMedicine*. 2018 Feb;28:303-310.
-